Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+ and Cl- flux in the lung

Journal of Bacteriology

Volumn 195, Issue 18, 2013, Pages 4013-4019

  Ballok, Alicia E ^a   O'Toole, George A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PROTEINASE; CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR INHIBITORY FACTOR; EXOPEPTIDASE; LIPOPOLYSACCHARIDE; PHENAZINE DERIVATIVE; PHOSPHOLIPASE; SODIUM CHANNEL; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

BACTERIAL VIRULENCE; BACTERIUM PILUS; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CELL SHAPE; CELL SURVIVAL; EPITHELIUM CELL; FLAGELLUM; ION TRANSPORT; OSMOSIS; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SHORT SURVEY;

BACTERIAL PROTEINS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPEPTIDASES; EPITHELIAL CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; LUNG; MODELS, MOLECULAR; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SODIUM CHLORIDE; VIRULENCE FACTORS;

EID: 84883268954     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.00339-13     Document Type: Short Survey

References (88)

1. Williams BJ, Dehnbostel J, Blackwell TS. 2010. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 15:1037-1056.
2. Tuder RM, Petrache I. 2012. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 122:2749-2755.
3. Sethi S, Murphy TF. 2001. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin. Microbiol. Rev. 14:336-363.
4. Döring G, Parameswaran IG, Murphy TF. 2011. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol. Rev. 35:124-146.
5. Kollef MH, Schuster DP. 1994. Ventilator-associated pneumonia: clinical considerations. AJR Am. J. Roentgenol. 163:1031-1035.
6. Kollef MH. 2013. Ventilator-associated complications, including infection-related complications: the way forward. Crit. Care Clin. 29:33-50.
7. Chastre J, Fagon JY. 2002. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165:867-903.
8. Chambers LA, Rollins BM, Tarran R. 2007. Liquid movement across the surface epithelium of large airways. Respir. Physiol. Neurobiol. 159:256-270.
9. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC, Boucher RC. 1995. CFTR as a cAMP-dependent regulator of sodium channels. Science 269:847-850.
10. + channels (ENaCs) in Xenopus oocytes coexpressing CFTR and ENaC. J. Physiol. 508(Pt 3):825-836.
11. Berdiev BK, Qadri YJ, Benos DJ. 2009. Assessment of the CFTR and ENaC association. Mol. Biosyst. 5:123-127.
12. Toczylowska-Mamińska R, Dolowy K. 2012. Ion transporting proteins of human bronchial epithelium. J. Cell. Biochem. 113:426-432.
13. Kunzelmann K, Schreiber R. 2012. Airway epithelial cells- hyperabsorption in CF? Int. J. Biochem. Cell Biol. 44:1232-1235.
14. + currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator. FEBS Lett. 400:341-344.
15. Ji HL, Chalfant ML, Jovov B, Lockhart JP, Parker SB, Fuller CM, Stanton BA, Benos DJ. 2000. The cytosolic termini of the beta- and gamma-ENaC subunits are involved in the functional interactions between cystic fibrosis transmembrane conductance regulator and epithelial sodium channel. J. Biol. Chem. 275:27947-27956.
16. Berdiev BK, Cormet-Boyaka E, Tousson A, Qadri YJ, Oosterveld-Hut HM, Hong JS, Gonzales PA, Fuller CM, Sorscher EJ, Lukacs GL, Benos DJ. 2007. Molecular proximity of cystic fibrosis transmembrane conductance regulator and epithelial sodium channel assessed by fluorescence resonance energy transfer. J. Biol. Chem. 282:36481-36488.
17. McIsaac SM, Stadnyk AW, Lin TJ. 2012. Toll-like receptors in the host defense against Pseudomonas aeruginosa respiratory infection and cystic fibrosis. J. Leukoc. Biol. 92:977-985.
18. Amiel E, Lovewell RR, O'Toole GA, Hogan DA, Berwin B. 2010. Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming motility and is independent of flagellum expression. Infect. Immun. 78:2937-2945.
19. Kida Y, Higashimoto Y, Inoue H, Shimizu T, Kuwano K. 2008. A novel secreted protease from Pseudomonas aeruginosa activates NF-kappaB through protease-activated receptors. Cell. Microbiol. 10:1491-1504.
20. Read RC, Roberts P, Munro N, Rutman A, Hastie A, Shryock T, Hall R, McDonald-Gibson W, Lund V, Taylor G, et al. 1992. Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating. J. Appl. Physiol. 72:2271-2277.
21. Rada B, Leto TL. 2013. Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas aeruginosa airway infections. Trends Microbiol. 21:73-81.
22. Hunter RC, Klepac-Ceraj V, Lorenzi MM, Grotzinger H, Martin TR, Newman DK. 2012. Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. Am. J. Respir. Cell Mol. Biol. 47:738-745.
23. Wolf P, Elsasser-Beile U. 2009. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int. J. Med. Microbiol. 299:161-176.
24. Deng Q, Barbieri JT. 2008. Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu. Rev. Microbiol. 62:271-288.
25. Liu PV. 1973. Exotoxins of Pseudomonas aeruginosa. I. Factors that influence the production of exotoxin A. J. Infect. Dis. 128:506-513.
26. Bleves S, Viarre V, Salacha R, Michel GP, Filloux A, Voulhoux R. 2010. Protein secretion systems in Pseudomonas aeruginosa: a wealth of pathogenic weapons. Int. J. Med. Microbiol. 300:534-543.
27. Engel J, Balachandran P. 2009. Role of Pseudomonas aeruginosa type III effectors in disease. Curr. Opin. Microbiol. 12:61-66.
28. Barbieri JT, Sun J. 2004. Pseudomonas aeruginosa ExoS and ExoT. Rev. Physiol. Biochem. Pharmacol. 152:79-92.
29. Ochoa CD, Alexeyev M, Pastukh V, Balczon R, Stevens T. 2012. Pseudomonas aeruginosa exotoxin Y is a promiscuous cyclase that increases endothelial tau phosphorylation and permeability. J. Biol. Chem. 287:25407-25418.
30. Anderson DM, Frank DW. 2012. Five mechanisms of manipulation by bacterial effectors: a ubiquitous theme. PLoS Pathog. 8:e1002823.
31. Engel J, Eran Y. 2012. Subversion of mucosal barrier polarity by Pseudomonas aeruginosa. Front. Microbiol. 2:114.
32. Lau GW, Hassett DJ, Britigan BE. 2005. Modulation of lung epithelial functions by Pseudomonas aeruginosa. Trends Microbiol. 13:389-397.
33. Park PW, Pier GB, Hinkes MT, Bernfield M. 2001. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411:98-102.
34. Alcorn JF, Wright JR. 2004. Degradation of pulmonary surfactant proteinDby Pseudomonas aeruginosa elastase abrogates innate immune function. J. Biol. Chem. 279:30871-30879.
35. Malloy JL, Veldhuizen RA, Thibodeaux BA, O'Callaghan RJ, Wright JR. 2005. Pseudomonas aeruginosa protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:L409-L418.
36. Ochsner UA, Snyder A, Vasil AI, Vasil ML. 2002. Effects of the twinarginine translocase on secretion of virulence factors, stress response, and pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 99:8312-8317.
37. Schmiel DH, Miller VL. 1999. Bacterial phospholipases and pathogenesis. Microbes Infect. 1:1103-1112.
38. Barker AP, Vasil AI, Filloux A, Ball G, Wilderman PJ, Vasil ML. 2004. A novel extracellular phospholipase C of Pseudomonas aeruginosa is required for phospholipid chemotaxis. Mol. Microbiol. 53:1089-1098.
39. Terada LS, Johansen KA, Nowbar S, Vasil AI, Vasil ML. 1999. Pseudomonas aeruginosa hemolytic phospholipase C suppresses neutrophil respiratory burst activity. Infect. Immun. 67:2371-2376.
40. Pena J, Fu Z, Schwarzer C, Machen TE. 2009. Pseudomonas aeruginosa inhibition of flagellin-activated NF-kappaB and interleukin-8 by human airway epithelial cells. Infect. Immun. 77:2857-2865.
41. Kishioka C, Okamoto K, Hassett DJ, de Mello D, Rubin BK. 1999. Pseudomonas aeruginosa alginate is a potent secretagogue in the isolated ferret trachea. Pediatr. Pulmonol. 27:174-179.
42. Ohman DE, Chakrabarty AM. 1981. Genetic mapping of chromosomal determinants for the production of the exopolysaccharide alginate in a Pseudomonas aeruginosa cystic fibrosis isolate. Infect. Immun. 33:142-148.
43. Deretic V, Gill JF, Chakrabarty AM. 1987. Gene algD coding for GDPMinireview mannose dehydrogenase is transcriptionally activated in mucoid Pseudomonas aeruginosa. J. Bacteriol. 169:351-358.
44. Tingpej P, Smith L, Rose B, Zhu H, Conibear T, Al Nassafi K, Manos J, Elkins M, Bye P, Willcox M, Bell S, Wainwright C, Harbour C. 2007. Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis. J. Clin. Microbiol. 45:1697-1704.
45. Hogardt M, Heesemann J. 2013. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr. Top. Microbiol. Immunol. 358:91-118.
46. Oliver A, Mena A. 2010. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin. Microbiol. Infect. 16:798-808.
47. Ballok AE, Bahl CD, Dolben EL, Lindsay AK, St Laurent JD, Hogan DA, Madden DR, O'Toole GA. 2012. Epoxide-mediated CifR repression of cif gene expression utilizes two binding sites in Pseudomonas aeruginosa. J. Bacteriol. 194:5315-5324.
48. Swiatecka-Urban A, Moreau-Marquis S, Maceachran DP, Connolly JP, Stanton CR, Su JR, Barnaby R, O'Toole GA, Stanton BA. 2006. Pseudomonas aeruginosa inhibits endocytic recycling of CFTR in polarized human airway epithelial cells. Am. J. Physiol. Cell Physiol. 290:C862-872.
49. MacEachran DP, Ye S, Bomberger JM, Hogan DA, Swiatecka-Urban A, Stanton BA, O'Toole GA. 2007. The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infect. Immun. 75:3902-3912.
50. Bahl CD, Morisseau C, Bomberger JM, Stanton BA, Hammock BD, O'Toole GA, Madden DR. 2010. Crystal structure of the CFTR inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. J. Bacteriol. 192:1785-1795.
51. Bahl CD, MacEachran DP, O'Toole GA, Madden DR. 2010. Purification, crystallization and preliminary X-ray diffraction analysis of Cif, a virulence factor secreted by Pseudomonas aeruginosa. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 66:26-28.
52. Bahl CD, Madden DR. 2012. Pseudomonas aeruginosa Cif defines a distinct class of alpha/beta epoxide hydrolases utilizing a His/Tyr ringopening pair. Protein Pept. Lett. 19:186-193.
53. Swiatecka-Urban A, Brown A, Moreau-Marquis S, Renuka J, Coutermarsh B, Barnaby R, Karlson KH, Flotte TR, Fukuda M, Langford GM, Stanton BA. 2005. The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells. J. Biol. Chem. 280:36762-36772.
54. Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K, Bache KG, Papsin B, Zerangue N, Stenmark H, Lukacs GL. 2004. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J. Cell Biol. 164:923-933.
55. Bomberger JM, Ye S, Maceachran DP, Koeppen K, Barnaby RL, O'Toole GA, Stanton BA. 2011. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog. 7:e1001325.
56. Ye S, MacEachran DP, Hamilton JW, O'Toole GA, Stanton BA. 2008. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Am. J. Physiol. Cell Physiol. 295:C807-818.
57. Mashburn LM, Jett AM, Akins DR, Whiteley M. 2005. Staphylococcus aureus serves as an iron source for Pseudomonas aeruginosa during in vivo coculture. J. Bacteriol. 187:554-566.
58. MacEachran DP, Stanton BA, O'Toole GA. 2008. Cif is negatively regulated by the TetR family repressor CifR. Infect. Immun. 76:3197-3206.
59. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Hoiby N, Molin S. 2012. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat. Rev. Microbiol. 10:841-851.
60. Bomberger JM, Maceachran DP, Coutermarsh BA, Ye S, O'Toole GA, Stanton BA. 2009. Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog. 5:e1000382.
61. Painter RG, Bonvillain RW, Valentine VG, Lombard GA, LaPlace SG, Nauseef WM, Wang G. 2008. The role of chloride anion and CFTR in killing of Pseudomonas aeruginosa by normal and CF neutrophils. J. Leukoc. Biol. 83:1345-1353.
62. Bonvillain RW, Painter RG, Adams DE, Viswanathan A, Lanson NA, Jr, Wang G. 2010. RNA interference against CFTR affects HL60-derived neutrophil microbicidal function. Free Radic. Biol. Med. 49:1872-1880.
63. Laarman AJ, Bardoel BW, Ruyken M, Fernie J, Milder FJ, van Strijp JA, Rooijakkers SH. 2012. Pseudomonas aeruginosa alkaline protease blocks complement activation via the classical and lectin pathways. J. Immunol. 188:386-393.
64. Lazdunski A, Guzzo J, Filloux A, Bally M, Murgier M. 1990. Secretion of extracellular proteins by Pseudomonas aeruginosa. Biochimie 72:147-156.
65. Pollack M. 1984. The virulence of Pseudomonas aeruginosa. Rev. Infect. Dis. 6(Suppl 3):S617-S626.
66. Wretlind B, Pavlovskis OR. 1981. The role of proteases and exotoxin A in the pathogenicity of Pseudomonas aeruginosa infections. Scand. J. Infect. Dis. Suppl. 29:13-19.
67. Inoue H, Nakagawa T, Morihara K. 1963. Pseudomonas aeruginosa proteinase. II. Molecular weight and molecular dimension. Biochim. Biophys. Acta 73:125-131.
68. Lomholt JA, Poulsen K, Kilian M. 2001. Epidemic population structure of Pseudomonas aeruginosa: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors. Infect. Immun. 69:6284-6295.
69. Firoved AM, Deretic V. 2003. Microarray analysis of global gene expression in mucoid Pseudomonas aeruginosa. J. Bacteriol. 185:1071-1081.
70. Jaffar-Bandjee MC, Lazdunski A, Bally M, Carrere J, Chazalette JP, Galabert C. 1995. Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa. J. Clin. Microbiol. 33: 924-929.
71. Baumann U, Wu S, Flaherty KM, McKay DB. 1993. Three-dimensional structure of the alkaline protease of Pseudomonas aeruginosa: a twodomain protein with a calcium binding parallel beta roll motif. EMBO J. 12:3357-3364.
72. Sarkisova S, Patrauchan MA, Berglund D, Nivens DE, Franklin MJ. 2005. Calcium-induced virulence factors associated with the extracellular matrix of mucoid Pseudomonas aeruginosa biofilms. J. Bacteriol. 187: 4327-4337.
73. Guzzo J, Pages JM, Duong F, Lazdunski A, Murgier M. 1991. Pseudomonas aeruginosa alkaline protease: evidence for secretion genes and study of secretion mechanism. J. Bacteriol. 173:5290-5297.
74. Guzzo J, Duong F, Wandersman C, Murgier M, Lazdunski A. 1991. The secretion genes of Pseudomonas aeruginosa alkaline protease are functionally related to those of Erwinia chrysanthemi proteases and Escherichia coli alpha-haemolysin. Mol. Microbiol. 5:447-453.
75. Duong F, Bonnet E, Geli V, Lazdunski A, Murgier M, Filloux A. 2001. The AprX protein of Pseudomonas aeruginosa: a new substrate for the Apr type I secretion system. Gene 262:147-153.
76. Kadurugamuwa JL, Beveridge TJ. 1997. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J. Antimicrob. Chemother. 40:615-621.
77. Feltzer RE, Gray RD, Dean WL, Pierce WM, Jr. 2000. Alkaline proteinase inhibitor of Pseudomonas aeruginosa. Interaction of native and N-terminally truncated inhibitor proteins with Pseudomonas metalloproteinases. J. Biol. Chem. 275:21002-21009.
78. Bardoel BW, van Kessel KP, van Strijp JA, Milder FJ. 2012. Inhibition of Pseudomonas aeruginosa virulence: characterization of the AprA-AprI interface and species selectivity. J. Mol. Biol. 415:573-583.
79. Gambello MJ, Kaye S, Iglewski BH. 1993. LasR of Pseudomonas aeruginosa is a transcriptional activator of the alkaline protease gene (apr) and an enhancer of exotoxin A expression. Infect. Immun. 61:1180-1184.
80. Nouwens AS, Beatson SA, Whitchurch CB, Walsh BJ, Schweizer HP, Mattick JS, Cordwell SJ. 2003. Proteome analysis of extracellular proteins regulated by the las and rhl quorum sensing systems in Pseudomonas aeruginosa PAO1. Microbiology 149:1311-1322.
81. Turner KH, Vallet-Gely I, Dove SL. 2009. Epigenetic control of virulence gene expression in Pseudomonas aeruginosa by a LysR-type transcription regulator. PLoS Genet. 5:e1000779.
82. Shigematsu T, Fukushima J, Oyama M, Tsuda M, Kawamoto S, Okuda K. 2001. Iron-mediated regulation of alkaline proteinase production in Pseudomonas aeruginosa. Microbiol. Immunol. 45:579-590.
83. Kim SJ, Park RY, Kang SM, Choi MH, Kim CM, Shin SH. 2006. Pseudomonas aeruginosa alkaline protease can facilitate siderophoremediated iron-uptake via the proteolytic cleavage of transferrins. Biol. Pharm. Bull. 29:2295-2300.
84. Bardoel BW, van der Ent S, Pel MJ, Tommassen J, Pieterse CM, van Kessel KP, van Strijp JA. 2011. Pseudomonas evades immune recognition of flagellin in both mammals and plants. PLoS Pathog. 7:e1002206.
85. Hong YQ, Ghebrehiwet B. 1992. Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3. Clin. Immunol. Immunopathol. 62:133-138.
86. Parmely M, Gale A, Clabaugh M, Horvat R, Zhou WW. 1990. Proteolytic inactivation of cytokines by Pseudomonas aeruginosa. Infect. Immun. 58:3009-3014.
87. Butterworth MB, Zhang L, Heidrich EM, Myerburg MM, Thibodeau PH. 2012. Activation of the epithelial sodium channel (ENaC) by the alkaline protease from Pseudomonas aeruginosa. J. Biol. Chem. 287: 32556-32565.
88. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365:1663-1672.